MicroRNAs (miRNAs) have emerged as key regulators of gene expression stability implicated in cell proliferation, apoptosis, and development, whereas their altered expression has been associated with various pathological disorders. The objective of this study was to assess the expression profile of miRNAs and their predicted target genes in placentas from patients with preeclampsia (PC) and preterm (PT) labor as compared to normal term (NT) pregnancies. Using microarray profiling of 820 miRNAs and 18,630 mRNA transcripts, the analysis indicated that 283 of these miRNAs and 9119 mRNAs were expressed in all placentas, of which the relative expression of 20 miRNAs (P < .05 and ≥1.5-fold) and 120 mRNAs (P < .05, and 2-fold cutoff) was differentially expressed in PT and PC as compared to NT. The expression of miR-15b, miR-181a, miR-200C, miR-210, miR-296–3p, miR-377, miR-483–5p, and miR-493 and a few of their predicted target genes: matrix metalloproteinases (MMP-1, MMP-9), a disintegrin and metalloproteinase domains (ADAM-17, ADAM-30), tissue inhibitor of metalloproteinase 3 (TIMP-3); suppressor of cytokine signaling 1 (SOCS1); Stanniocalcin (STC2); corticotropin-releasing hormone (CRH), CRH-binding protein (CRHBP); and endothelin-2 (EDN2) were validated in these cohorts using real-time polymerase chain reaction (PCR), some displaying an inverse correlation with the expression of their predicted target genes. Functional analysis indicated that the products of these genes regulate cellular activities considered critical in normal placental functions and those affected by PC and PT labor. In conclusion, the results provide further evidence that placentas affected by PC and PT labor display an altered expression of a number of miRNAs with potential regulatory functions on the expression of specific target genes whose altered expression and function have been associated with these pregnancy complications.
DeFrancoETeramoKMugliaL. Genetic influences on preterm birth. Semin Reprod Med. 2007;25(1):40–51.
3.
DildyGA 3rdBelfortMASmulianJC. Preeclampsia recurrence and prevention. Semin Perinatol. 2007;31(3):135–141.
4.
Faye-PetersenOM. The placenta in preterm birth. J Clin Pathol. 2008;61(12):1261–1275.
5.
GencMRSchantz-DunnJ. The role of gene-environment interaction in predicting adverse pregnancy outcome. Best Pract Res Clin Obstet Gynaecol. 2007;21(3):491–504.
6.
GilbertJSNijlandMJKnoblichP. Placental ischemia and cardiovascular dysfunction in preeclampsia and beyond: making the connections. Expert Rev Cardiovasc Ther. 2008;6(10):1367–1377.
7.
GoldenbergRLCulhaneJFIamsJDRomeroR. Epidemiology and causes of preterm birth. Lancet. 2008;371(9606):75–84.
8.
HolstDGarnierY. Preterm birth and inflammation-The role of genetic polymorphisms. Eur J Obstet Gynecol Reprod Biol. 2008;141(1):3–9.
9.
PennellCEJacobssonBWilliamsSM. Genetic epidemiologic studies of preterm birth: guidelines for research. Am J Obstet Gynecol. 2007;196(2):107–118.
10.
RomeroREspinozaJGoncalvesLFKusanovicJPFrielLHassanS. The role of inflammation and infection in preterm birth. Semin Reprod Med. 2007;25(1):21–39.
11.
WinnVDGormleyMPaquetAC. Severe preeclampsia-related changes in gene expression at the maternal-fetal interface include sialic acid-binding immunoglobulin-like lectin-6 and pappalysin-2. Endocrinology. 2009;150(1):452–462.
12.
BartonJRSibaiBM. Prediction and prevention of recurrent preeclampsia. Obstet Gynecol. 2008;112(2 Pt 1):359–372.
13.
EnquobahrieDAMellerMRiceKPsatyBMSiscovickDSWilliamsMA. Differential placental gene expression in preeclampsia. Am J Obstet Gynecol. 2008;199(5):566–511.
14.
GackSMarmeAMarmeF. Preeclampsia: increased expression of soluble ADAM 12. J Mol Med. 2005;83(11):887–896.
15.
GuptaAKHaslerPHolzgreveWHahnS. Neutrophil NETs: a novel contributor to preeclampsia-associated placental hypoxia?Semin Immunopathol. 2007;29(2):163–167.
16.
HanJYKimYSChoGJ. Altered gene expression of caspase-10, death receptor-3 and IGFBP-3 in preeclamptic placentas. Mol Cells. 2006;22(2):168–174.
17.
HawfieldAFreedmanBI. Pre-eclampsia: the pivotal role of the placenta in its pathophysiology and markers for early detection. Ther Adv Cardiovasc Dis. 2009;3(1):65–73.
18.
LaMarcaBDRyanMJGilbertJSMurphySRGrangerJP. Inflammatory cytokines in the pathophysiology of hypertension during preeclampsia. Curr Hypertens Rep. 2007;9(6):480–485.
19.
MutterWPKarumanchiSA. Molecular mechanisms of preeclampsia. Microvasc Res. 2008;75(1):1–8.
20.
NejatizadehAStobdanTMalhotraNPashaMA. The genetic aspects of pre-eclampsia: achievements and limitations. Biochem Genet. 2008;46(7–8):451–479.
21.
OkazakiSSekizawaAPurwosunuYFarinaAWibowoNOkaiT. Placenta-derived, cellular messenger RNA expression in the maternal blood of preeclamptic women. Obstet Gynecol. 2007;110(5):1130–1136.
22.
LockwoodCJKrikunGCazeRRahmanMBuchwalderLFSchatzF. Decidual cell-expressed tissue factor in human pregnancy and its involvement in hemostasis and preeclampsia-related angiogenesis. Ann N Y Acad Sci. 2008;1127:67–72.
23.
RusterholzCHahnSHolzgreveW. Role of placentally produced inflammatory and regulatory cytokines in pregnancy and the etiology of preeclampsia. Semin Immunopathol. 2007;29(2):151–162.
24.
ShibuyaM. Vascular endothelial growth factor-dependent and -independent regulation of angiogenesis. BMB Rep. 2008;41(4):278–286.
25.
XiaYZhouCCRaminSMKellemsRE. Angiotensin receptors, autoimmunity, and preeclampsia. J Immunol. 2007;179(6):3391–3395.
26.
LaMarcaBDAlexanderBTGilbertJS. Pathophysiology of hypertension in response to placental ischemia during pregnancy: a central role for endothelin?Gend Med. 2008;5(Suppl A):S133–S138.
27.
MenonR. Spontaneous preterm birth, a clinical dilemma: etiologic, pathophysiologic and genetic heterogeneities and racial disparity. Acta Obstet Gynecol Scand. 2008;87(6):590–600.
28.
NesinM. Genetic basis of preterm birth. Front Biosci. 2007;12:115–124.
29.
BaekDVillenJShinCCamargoFDGygiSPBartelDP. The impact of microRNAs on protein output. Nature. 2008;455(7209):64–71.
30.
EngelsBMHutvagnerG. Principles and effects of microRNA-mediated post-transcriptional gene regulation. Oncogene. 2006;25(46):6163–6169.
HagenJWLaiEC. microRNA control of cell-cell signaling during development and disease. Cell Cycle. 2008;7(15):2327–2332.
34.
CalinGACroceCM. MicroRNAs and chromosomal abnormalities in cancer cells. Oncogene. 2006;25(46):6202–6210.
35.
ChoWC. OncomiRs: the discovery and progress of microRNAs in cancers. Mol Cancer. 2007;6:60.
36.
DengSCalinGACroceCMCoukosGZhangL. Mechanisms of microRNA deregulation in human cancer. Cell Cycle. 2008;7(17):2643–2646.
37.
GregoryPABrackenCPBertAGGoodallGJ. MicroRNAs as regulators of epithelial-mesenchymal transition. Cell Cycle. 2008;7(20):3112–3118.
38.
LeeYSDuttaA. MicroRNAs in Cancer. Annu Rev Pathol. 2008;4:199–227.
39.
ChimSSShingTKHungEC. Detection and characterization of placental microRNAs in maternal plasma. Clin Chem. 2008;54(3):482–490.
40.
DonkerRBMouilletJFNelsonDMSadovskyY. The expression of Argonaute2 and related microRNA biogenesis proteins in normal and hypoxic trophoblasts. Mol Hum Reprod. 2007;13(4):273–279.
41.
MontenegroDRomeroRKimSS. Expression patterns of microRNAs in the chorioamniotic membranes: a role for microRNAs in human pregnancy and parturition. J Pathol. 2009;217(1):113–121.
42.
PinelesBLRomeroRMontenegroD. Distinct subsets of microRNAs are expressed differentially in the human placentas of patients with preeclampsia. Am J Obstet Gynecol. 2007;196(3):261–266.
43.
PanQLuoXToloubeydokhtiTCheginiN. The expression profile of micro-RNA in endometrium and endometriosis and the influence of ovarian steroids on their expression. Mol Hum Reprod. 2007;13(11):797–806.
44.
PanQLuoXCheginiN. Genomic and proteomic profiling I: leiomyomas in African Americans and Caucasians. Reprod Biol Endocrinol. 2007;5:34.
45.
PanQLuoXToloubeydokhtiTCheginiN. The expression profile of micro-RNA in endometrium and endometriosis and the influence of ovarian steroids on their expression. Mol Hum Reprod. 2007;13(11):797–806.
46.
ZhuXMHanTSargentILYinGWYaoYQ. Differential expression profile of microRNAs in human placentas from preeclamptic pregnancies vs normal pregnancies. Am J Obstet Gynecol. 2009;200(6):661E1–E7.
47.
CartyDMDellesCDominiczakAF. Novel biomarkers for predicting preeclampsia. Trends Cardiovasc Med. 2008;18(5):186–194.
48.
CockleJVGopichandranNWalkerJJLeveneMIOrsiNM. Matrix metalloproteinases and their tissue inhibitors in preterm perinatal complications. Reprod Sci. 2007;14(7):629–645.
49.
EastabrookGHuYvon DadelszenP. The role of decidual natural killer cells in normal placentation and in the pathogenesis of preeclampsia. J Obstet Gynaecol Can. 2008;30(6):467–476.
50.
MuhleRAPavlidisPGrundyWNHirschE. A high-throughput study of gene expression in preterm labor with a subtractive microarray approach. Am J Obstet Gynecol. 2001;185(3):716–724.
51.
SitrasVPaulssenRHGronaasH. Differential placental gene expression in severe preeclampsia. Placenta. 2009;30(5):424–433.
52.
TrompGKuivaniemiHRomeroR. Genome-wide expression profiling of fetal membranes reveals a deficient expression of proteinase inhibitor 3 in premature rupture of membranes. Am J Obstet Gynecol. 2004;191(4):1331–1338.
53.
WangQWangYMintoAW. MicroRNA-377 is up-regulated and can lead to increased fibronectin production in diabetic nephropathy. FASEB J. 2008;22(12):4126–4135.
54.
CornPG. Hypoxic regulation of miR-210: shrinking targets expand HIF-1’s influence. Cancer Biol Ther. 2008;7(2):265–267.
55.
CrosbyMEKulshreshthaRIvanMGlazerPM. MicroRNA regulation of DNA repair gene expression in hypoxic stress. Cancer Res. 2009;69(3):1221–1229.
56.
FasanaroPD’AlessandraYDiSV. MicroRNA-210 modulates endothelial cell response to hypoxia and inhibits the receptor tyrosine kinase ligand Ephrin-A3. J Biol Chem. 2008;283(23):15878–15883.
57.
GiannakakisASandaltzopoulosRGreshockJ. miR-210 links hypoxia with cell cycle regulation and is deleted in human epithelial ovarian cancer. Cancer Biol Ther. 2008;7(2):255–264.
XiaoLJYuanJXSongXXLiYCHuZYLiuYX. Expression and regulation of stanniocalcin 1 and 2 in rat uterus during embryo implantation and decidualization. Reproduction. 2006;131(6):1137–1149.
60.
RaffettoJDKhalilRA. Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease. Biochem Pharmacol. 2008;75(2):346–359.
61.
SoleymanlouNJurisicaINevoO. Molecular evidence of placental hypoxia in preeclampsia. J Clin Endocrinol Metab. 2005;90(7):4299–4308.
62.
SpencerKVereeckenACowansNJ. Maternal serum ADAM12s as a potential marker of trisomy 21 prior to 10 weeks of gestation. Prenat Diagn. 2008;28(3):209–211.
63.
StoneALKroegerMSangQX. Structure-function analysis of the ADAM family of disintegrin-like and metalloproteinase-containing proteins (review). J Protein Chem. 1999;18(4):447–465.
64.
ZhuHLeungPCMacCalmanCD. Expression of ADAMTS-5/implantin in human decidual stromal cells: regulatory effects of cytokines. Hum Reprod. 2007;22(1):63–74.
65.
AntonLMerrillDCNevesLAA. The Uterine placental bed Renin-Angiotensin system in normal and preeclamptic pregnancy. Endocrinology. 2009;150(9):4316–4325.
66.
ChoongMLYangHHMcNieceI. MicroRNA expression profiling during human cord blood-derived CD34 cell erythropoiesis. Exp Hematol. 2007;35(4):551–564.
67.
WangXTangSLeSY. Aberrant expression of oncogenic and tumor-suppressive microRNAs in cervical cancer is required for cancer cell growth. PLoS ONE. 2008;3(7):e2557.
68.
XiaHQiYNgSS. MicroRNA-15b regulates cell cycle progression by targeting cyclins in glioma cells. Biochem Biophys Res Commun. 2009;380(2):205–210.
69.
GrammatopoulosDK. Placental corticotrophin-releasing hormone and its receptors in human pregnancy and labour: still a scientific enigma. J Neuroendocrinol. 2008;20(4):432–438.
70.
WangJQiuQHaiderMBellMGruslinAChristiansJK. Expression of pregnancy-associated plasma protein A2 during pregnancy in human and mouse. J Endocrinol. 2009;202(3):337–345.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
